These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15656832)

  • 1. Pimecrolimus 1% cream for perianal atopic dermatitis.
    Kreuter A; Hochdorfer B; Altmeyer P; Gambichler T
    Br J Dermatol; 2005 Jan; 152(1):186-7. PubMed ID: 15656832
    [No Abstract]   [Full Text] [Related]  

  • 2. Pimecrolimus 1% cream for the treatment of atopic dermatitis.
    Wolff K
    Skin Therapy Lett; 2005 Oct; 10(8):1-6. PubMed ID: 16292456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison.
    Draelos Z; Nayak A; Pariser D; Shupack JL; Chon K; Abrams B; Paul CF
    J Am Acad Dermatol; 2005 Oct; 53(4):602-9. PubMed ID: 16198779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of pimecrolimus cream 1% in children for the treatment of mild to moderate atopic dermatitis.
    Cohen B
    Clin Pediatr (Phila); 2007 Jan; 46(1):7-15. PubMed ID: 17164503
    [No Abstract]   [Full Text] [Related]  

  • 5. Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks.
    Qureshi AA; Fischer MA
    Arch Dermatol; 2006 May; 142(5):633-7. PubMed ID: 16702502
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years.
    Paul C; Cork M; Rossi AB; Papp KA; Barbier N; de Prost Y
    Pediatrics; 2006 Jan; 117(1):e118-28. PubMed ID: 16361223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial.
    Gollnick H; Kaufmann R; Stough D; Heikkila H; Andriano K; Grinienko A; Jimenez P;
    Br J Dermatol; 2008 May; 158(5):1083-93. PubMed ID: 18341665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Topical calcineurin inhibitors in atopic eczema -- pro].
    Wollenberg A
    Dtsch Med Wochenschr; 2006 Jul; 131(28-29):1614. PubMed ID: 16823713
    [No Abstract]   [Full Text] [Related]  

  • 9. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.
    Hebert AA
    Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and cytological effects of pimecrolimus cream 1% after resolution of active atopic dermatitis lesions by topical corticosteroids: a randomized controlled trial.
    Bangert C; Strober BE; Cork M; Ortonne JP; Luger T; Bieber T; Ferguson A; Ecker RC; Kopp T; Weise-Riccardi S; Guettner A; Stingl G
    Dermatology; 2011 Feb; 222(1):36-48. PubMed ID: 21150167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tacrolimus and pimecrolimus ointments in the treatment of atopic eczema].
    Reitamo S; Remitz A
    Duodecim; 2003; 119(9):825-7. PubMed ID: 12815980
    [No Abstract]   [Full Text] [Related]  

  • 12. [How I treat ... atopic dermatitis by topical pimecrolimus (Elidel). The emerging paradigm of calcineurin inhibitors].
    Piérard-Franchimont C; Quatresooz P; Piérard GE
    Rev Med Liege; 2005 Mar; 60(3):136-40. PubMed ID: 15884695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
    Munzenberger PJ; Montejo JM
    Pharmacotherapy; 2007 Jul; 27(7):1020-8. PubMed ID: 17594208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis.
    Aschoff R; Schwanebeck U; Bräutigam M; Meurer M
    Exp Dermatol; 2009 Jan; 18(1):24-9. PubMed ID: 18637133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life].
    Sunderkötter C; Weiss JM; Bextermöller R; Löffler H; Schneider D
    J Dtsch Dermatol Ges; 2006 Apr; 4(4):301-6. PubMed ID: 16638059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis].
    van der Laan JR
    Ned Tijdschr Geneeskd; 2005 Aug; 149(32):1816; author reply 1817. PubMed ID: 16121669
    [No Abstract]   [Full Text] [Related]  

  • 17. Topical treatment for atopic dermatitis in the 21st century.
    Johnson SM; Kincannon JM; Dudney DL;
    J Ark Med Soc; 2004 Sep; 101(3):86-90. PubMed ID: 15384500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life.
    McKenna SP; Whalley D; de Prost Y; Staab D; Huels J; Paul CF; van Assche D
    J Eur Acad Dermatol Venereol; 2006 Mar; 20(3):248-54. PubMed ID: 16503881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream.
    Abramovits W; Fleischer AB; Jaracz E; Breneman D
    J Drugs Dermatol; 2008 Dec; 7(12):1153-8. PubMed ID: 19137769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovative use of topical calcineurin inhibitors.
    Lin AN
    Dermatol Clin; 2010 Jul; 28(3):535-45. PubMed ID: 20510763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.